新型多金属氧酸盐药物{BiW8O30}对肝癌SK-HEP-1细胞的抑制作用

doi:10.3969/j.issn.1004-616x.2022.01.009

癌变·畸变·突变 ›› 2022, Vol. 34 ›› Issue (1): 47-52,66.doi: 10.3969/j.issn.1004-616x.2022.01.009

新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用

祝欣萍¹, 贾迪¹, 林少辉¹, 刘晨¹, 李婧铱¹, 赵炜明^1,2

1. 齐齐哈尔医学院医学技术学院, 黑龙江齐齐哈尔 161006;
2. 黑龙江中医药大学, 黑龙江哈尔滨 150040

收稿日期:2021-10-09 修回日期:2021-12-05 出版日期:2022-01-31 发布日期:2022-02-15
通讯作者: 赵炜明,zhaowm1969@126.com E-mail:赵炜明,zhaowm1969@126.com
作者简介:祝欣萍,E-mail:172324344@qq.com
基金资助:
中央支持地方高校发展改革资金人才培养支持计划项目；黑龙江省普通高等学校青年创新人才培养计划项目（UNPYSCT-2020084）；齐齐哈尔市科技计划联合引导项目（LHYD-202001）；黑龙江省省属本科高校基本科研业务费（2019-KYYWF-1255）

Inhibitory effects of a novel polyoxometalate drug {BiW₈O₃₀}on liver cancer SK-HEP-1 cells

ZHU Xinping¹, JIA Di¹, LIN Shaohui¹, LIU Chen¹, LI Jingyi¹, ZHAO Weiming^1,2

1. Medical Technology Department, Qiqihar Medical University, Qiqihar 161006;
2. Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang, China

Received:2021-10-09 Revised:2021-12-05 Online:2022-01-31 Published:2022-02-15

摘要/Abstract

摘要： 目的： 研究新型多金属氧酸盐药物{BiW₈O₃₀}对体外培养的肝癌细胞的作用及其机制。方法： 体外培养人肝癌细胞SK-HEP-1，实验组分别给予50、100、200、400 μmol/L的{BiW₈O₃₀}药液，对照组给予正常培养液，培养24和48 h后检测相应指标。采用细胞增殖实验检测细胞存活率并计算{BiW₈O₃₀}对SK-HEP-1细胞的半数抑制浓度（IC₅₀）；细胞集落形成实验检测集落形成数；划痕实验检测划痕愈合率；Transwell实验检测侵袭细胞数变化；荧光染色分析药物对细胞凋亡的影响。结果： 与对照组比较，50、100、200、400 μmol/L的{BiW₈O₃₀}处理24 h后，SK-HEP-1细胞存活率分别降低了29.98%、51.29%、65.81%、83.59%（P<0.01），48 h后分别降低了31.57%、66.23%、81.88%、83.97%（P<0.01）；IC₅₀分别为24 h时（102.07±1.38）μmol/L，48 h时（74.68±0.91）μmol/L；50、100、200 μmol/L的{BiW₈O₃₀}处理2周后，SK-HEP-1细胞的集落形成数分别降低了28.57%、63.27%、90.82%（P<0.01）；50、100、200 μmol/L的{BiW₈O₃₀}处理24 h后，SK-HEP-1细胞的划痕愈合率分别降低了8.47%、70.59%、80.83%（P<0.01），48 h后分别降低了19.56%、65.98%、75.49%（P<0.01）；SK-HEP-1的侵袭细胞数在24 h后分别降低了27.74%、45.51%、68.77%（P<0.01），48 h后分别降低了47.03%、72.20%、84.07%（P<0.01）。荧光染色后观察发现{BiW₈O₃₀}处理后的肝癌细胞皱缩，细胞核固缩、碎裂，出现凋亡小体。结论： 新型多金属氧酸盐药物{BiW₈O₃₀}通过抑制肝癌SK-HEP-1细胞的增殖、集落形成、迁移和侵袭能力以及诱导细胞凋亡发挥体外抗肿瘤作用。

关键词: {BiW₈O₃₀}, 肝癌, SK-HEP-1细胞, 抗肿瘤作用

Abstract: OBJECTIVE: To explore the effects and mechanisms of action of a new polyoxometalate drug {BiW₈O₃₀} in liver cancer cells. METHODS: Human hepatocellular carcinoma cell line SK-HEP-1 was cultured and treated with 50,100,200 and 400 μmol/L {BiW₈O₃₀} solution,respectively. The control group was given normal culture medium. The corresponding indexes were detected after 24 and 48 h of culture. Cell proliferation assay was used to detect cell viability and half maximal inhibitory concentration (IC₅₀);cell colony formation experiment was used to detect number of colony formation;wound healing rate was detected by scratch test;Transwell assay was used to detect the number of invasive cells;the effect of drugs on apoptosis was analyzed by fluorescence staining. RESULTS: After treatment with 50,100,200,400 μmol/L {BiW₈O₃₀} for 24 and 48 h,the survival rate of SK-HEP-1 cells decreased by 29.98%,51.29%,65.81%,83.59% and 31.57%,66.23%,81.88%,83.97%,respectively (P<0.01),compared with the control group. In addition,IC₅₀ were (102.07±1.38) and (74.68±0.91) μmol/L,respectively. After 2 weeks of treatment with 50,100,and 200 μmol/L {BiW₈O₃₀},the number of colony formation of SK-HEP-1 cells decreased by 28.57%,63.27%,and 90.82%,respectively (P<0.01). After treatment with 50,100,200 μmol/L {BiW₈O₃₀} for 24 and 48 h,the scratch healing rate of SK-HEP-1 cells decreased by 8.47%,70.59%,80.83% and 19.56%,65.98%,75.49%,respectively (P<0.01),the number of invaded cells of SK-HEP-1 decreased by 27.74%,45.51%,68.77% and 47.03%,72.20%,84.07% (P<0.01). Observation after fluorescent staining revealed that the liver cancer cells treated with {BiW₈O₃₀} shrank,the nuclei shrank,fragmented,and apoptotic bodies appeared. CONCLUSION: The new polyoxometalate drug {BiW₈O₃₀} was toxic to SK-HEP-1 cancer cells in vitro by inhibiting the proliferation,colony formation,migration and invasion,and by inducing cell apoptosis.

Key words: {BiW₈O₃₀}, hepatocellular carcinoma, SK-HEP-1 cells, anti-tumor effect

中图分类号:

R735.7

祝欣萍, 贾迪, 林少辉, 刘晨, 李婧铱, 赵炜明. 新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用[J]. 癌变·畸变·突变, 2022, 34(1): 47-52,66.

ZHU Xinping, JIA Di, LIN Shaohui, LIU Chen, LI Jingyi, ZHAO Weiming. Inhibitory effects of a novel polyoxometalate drug {BiW₈O₃₀}on liver cancer SK-HEP-1 cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 47-52,66.

参考文献

[1] GALICIA-MORENO M, SILVA-GOMEZ J A, LUCANO-LANDEROS S, et al. Liver cancer:therapeutic challenges and the importance of experimental models[J]. Can J Gastroenterol Hepatol, 2021, 2021:1-10.
[2] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3):209-249.
[3] ANWANWAN D, SINGH S K, SINGH S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim et Biophys Acta BBA Rev Cancer, 2020, 1873(1):188314.
[4] KUDO M. Targeted and immune therapies for hepatocellular carcinoma:predictions for 2019 and beyond[J]. World J Gastroenterol, 2019, 25(7):789-807.
[5] YANG J D, HAINAUT P, GORES G J, et al. A global view of hepatocellular carcinoma:trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[6] SAZANI G, POPE MT. Organotin and organogermanium linkers for simple, direct functionalization of polyoxotungstates[J]. Dalton Trans, 2004, 7(13):1989-1994.
[7] RAZAVI S F, BAMOHARRAM F F, HASHEMI T, et al. Nanolipid-loaded preyssler polyoxometalate:synthesis, characterization and invitro inhibitory effects on HepG2 tumor cells[J]. Toxicol Vitro, 2020, 68:104917.
[8] WANG X H, LIU J F, LI J X, et al. Synthesis and antitumor activity of cyclopentadienyltitanium substituted polyoxotungstate[CoW₁₁O₃₉(CpTi)]₇-(Cp=η₅-C₅H₅)[J]. J Inorg Biochem, 2003, 94(3):279-284.
[9] DONG Z X, TAN R K, CAO J, et al. Discovery of polyoxometalate-based HDAC inhibitors with profound anticancer activity in vitro and in vivo[J]. Eur J Med Chem, 2011, 46(6):2477-2484.
[10] WANG L, YU K, ZHOU B B, et al. The inhibitory effects of a new cobalt-based polyoxometalate on the growth of human cancer cells[J]. Dalton Trans, 2014, 43(16):6070-6078.
[11] WANG L, ZHOU B B, YU K, et al. Novel antitumor agent, trilacunary Keggin-type tungstobismuthate, inhibits proliferation and induces apoptosis in human gastric cancer SGC-7901 cells[J]. Inorg Chem, 2013, 52(9):5119-5127.
[12] JOSHI A, GUPTA R, SINGH B, et al. Effective inhibitory activity against MCF-7, A549 and HepG2 cancer cells by a phosphomolybdate based hybrid solid[J]. Dalton Trans, 2020, 49(21):7069-7077.
[13] SUN H B, XU L, WANG Z X, et al. Polyoxometalate SbW9 regulates proliferation and apoptosis of NSCLC cells via PTEN-dependent AKT signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(18):7959-7967.
[14] JIA D, GONG L, LI Y, et al. {BiW₈O₃₀} exerts antitumor effect by triggering pyroptosis and upregulating reactive oxygen species[J]. Angew Chem Int Ed Engl, 2021, 60(39):21449-21456.
[15] LI C, FU Q, CAI J, et al. Effects of propofol on the proliferation and migration of liver cancer cells[J]. Exp Ther Med, 2021, 22(1):733.
[16] CHEN R, CHENG Q, OWUSU-ANSAH K G, et al. Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma[J]. Am J Cancer Res, 2018, 8(7):1297-1306.
[17] ZHAI J M, YIN X Y, LAI Y R, et al. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1[J]. Cancer Chemother Pharmacol, 2013, 71(5):1255-1264.
[18] SAMIR P, MALIREDDI R K S, KANNEGANTI T D. The PANoptosome:a deadly protein complex driving pyroptosis, apoptosis, and necroptosis (PANoptosis)[J]. Front Cell Infect Microbiol, 2020, 10:238.
[19] MALIREDDI R K S, KESAVARDHANA S, KANNEGANTI T D. ZBP₁ and TAK1:master regulators of NLRP3 inflammasome/pyroptosis, apoptosis, and necroptosis (PAN-optosis)[J]. Front Cell Infect Microbiol, 2019, 9:406.
[20] TANG D, KANG R, BERGHE T V, et al. The molecular machinery of regulated cell death[J]. Cell Res, 2019, 29(5):347-364.
[21] BEDOUI S, HEROLD M J, STRASSER A. Emerging connectivity of programmed cell death pathways and its physiological implications[J]. Nat Rev Mol Cell Biol, 2020, 21(11):678-695.

新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用

Inhibitory effects of a novel polyoxometalate drug {BiW₈O₃₀}on liver cancer SK-HEP-1 cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[2]	章菊, 叶书来, 张昌龙, 周倩. HepG2细胞外泌体冲击树突状细胞介导的抗肿瘤作用[J]. 癌变·畸变·突变, 2019, 31(1): 29-34.
[3]	丁文评, 陆元元, 童文侠, 周蔼斌, 孔祥, 陈意红. 氯喹通过激活P38MAPK通路诱导人肝癌HepG2细胞凋亡[J]. 癌变·畸变·突变, 2018, 30(6): 430-434.
[4]	赵吉, 刘文斌, 陈洪强, 刘晋祎, 杨惠芳, 曹佳. WFDC1基因在肝癌中的表达及其诊断和预后价值[J]. 癌变·畸变·突变, 2018, 30(4): 291-296.
[5]	刘丹, 焦良波, 张文, 王心怡, 陈涛, 胡卫. QHF复方对人肝癌Huh7细胞生长、侵袭及肿瘤干细胞表面标志物表达的影响[J]. 癌变·畸变·突变, 2018, 30(3): 171-175.
[6]	胡琼, 由淑萍, 刘涛, 汪波, 刘昕, 蒋远东. 肉苁蓉苯乙醇总苷抗肝癌作用的实验研究[J]. 癌变·畸变·突变, 2018, 30(3): 194-199.
[7]	刘芳, 秦双红, 赵燕霞. SREBP-1c基因过表达细胞模型的构建及对HepG2细胞脂滴含量的影响[J]. 癌变·畸变·突变, 2018, 30(1): 14-19.
[8]	黄永胜, 刘文斌, 韩飞, 崔志鸿, 敖琳, 曹佳, 刘晋祎. 肝癌组织中MPDZ基因拷贝数和表达变化及其诊断预后价值分析[J]. 癌变·畸变·突变, 2017, 29(3): 161-165.
[9]	宋蕾, 包青, 张焕铃. RNAi技术在肝癌研究中的应用[J]. 癌变·畸变·突变, 2016, 28(3): 236-238,242.
[10]	宋蕾, 王昭, 张焕铃. microRNA在肝癌诊断、治疗和预后中的作用研究进展[J]. 癌变·畸变·突变, 2015, 27(4): 325-328.
[11]	陈佳红, 张航, 赖怡, 姜岩, 陈涛. 三氯乙烯对B6C3F1雄性小鼠肝脏和肾脏中细胞增殖相关基因表达和DNA甲基化的影响[J]. 癌变·畸变·突变, 2015, 27(3): 211-215.
[12]	王灵巧，陈济安，舒为群. 原癌基因Gankyrin及其在肿瘤发生中的作用研究进展[J]. 癌变·畸变·突变, 2015, 27(1): 71-74.
[13]	王斌生. 精氨酸酶-1在原发性肝癌及肝转移癌鉴别中的作用[J]. 癌变·畸变·突变, 2014, 26(2): 113-116.
[14]	申艳梅,单保恩,刘丽华,张超,周凯旋,焦煜倩,焦文静. HSP70多肽复合物的抗肿瘤作用研究[J]. 癌变·畸变·突变, 2013, 25(4): 262-266.
[15]	王生育，罗芳洪，倪二茹，吕海燕，支黎明，颜江华，张顺浪. 免疫杀手细胞的体外扩增方法及其对肝癌细胞BEL-7402 的杀伤作用[J]. , 2012, 24(2): 121-124.